Research graph
References from Use of transdermal testosterone to treat menopausal symptoms in women with a history of breast cancer: a small, retrospective, open-label study. Local targets link to admitted publications; unresolved targets remain external evidence.
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
10.1200/jco.2015.64.3809 · 2016 · External reference
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe
10.1016/j.annonc.2022.07.1941 · 2022 · External reference
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2017.0146 · 2017 · External reference
The unmet needs of breast cancer survivors: is menopausal hormone therapy ever an option?
10.1097/gme.0000000000002568 · 2025 · External reference
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy
10.1007/s10549-007-9548-1 · 2008 · External reference
Safety of vaginal estrogens: a systematic review
10.1097/gme.0000000000001468 · 2020 · External reference
The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis
10.1016/j.clbc.2019.07.007 · 2019 · External reference
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)
2018 · External reference
Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks
10.1016/j.ajog.2024.10.054 · 2025 · External reference
Managing menopausal symptoms and associated clinical issues in breast cancer survivors
10.1210/jc.2017-01138 · 2017 · External reference
Consensus statement for non-hormonal based treatments for menopausal symptoms
10.1177/2053369120930508 · 2020 · External reference
SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials
10.1007/s11606-013-2535-9 · 2014 · External reference
Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update
10.3332/ecancer.2019.909 · 2019 · External reference
Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany
10.1097/gme.0000000000002611 · 2025 · External reference
Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: a systematic review and meta-analysis
10.1097/aog.0000000000005812 · 2025 · External reference
Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer
10.1056/nejmoa2415566 · 2025 · External reference
Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors
10.1007/s10549-021-06117-7 · 2021 · External reference
Patient experience of menopause care after breast cancer in the UK: a cross-sectional study
10.1097/gme.0000000000002504 · 2025 · External reference
Breast cancer patients’ experience of menopause care in the UK: thematic analysis of free-text comments
10.1097/gme.0000000000002505 · 2025 · External reference
Global consensus position statement on the use of testosterone therapy for women
10.1080/13697137.2019.1637079 · 2019 · External reference
International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
10.1016/j.jsxm.2020.10.009 · 2021 · External reference
Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data
10.1016/s2213-8587(19)30189-5 · 2019 · External reference
Testosterone and estrone increase from the age of 70 years: findings from the sex hormones in older women study
10.1210/jc.2019-00743 · 2019 · External reference
Associations between low sex hormone concentrations and depression in older women: an observational study
10.1016/j.maturitas.2023.107822 · 2023 · External reference
Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial
10.1016/s2666-7568(22)00001-0 · 2022 · External reference
Associations between blood concentrations of sex hormones and physical function in community-dwelling older women: a prospective cohort study
10.1093/gerona/glad287 · 2024 · External reference
Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS)
10.1016/j.maturitas.2010.12.001 · 2011 · External reference
Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study
10.1007/s00737-024-01513-6 · 2024 · External reference
SAT-139 testosterone therapy and breast cancer risk in postmenopausal women: a systematic review and meta-analysis
10.1210/jendso/bvaf149.1989 · 2025 · External reference
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
10.1038/s41591-020-01168-7 · 2021 · External reference
Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate
10.3892/mmr.2015.3427 · 2015 · External reference
The testosterone prescribing practice of BMS menopause specialists
10.1177/2053369120985743 · 2021 · External reference
A survey of brazilian gynecologists’ prescribing practices and attitudes towards testosterone use in women.
10.1097/gme.0000000000002752 · 2026 · External reference
Menopausal hormone therapy for breast cancer patients: what is the current evidence?
10.1097/gme.0000000000002627 · 2025 · External reference
Systemic estradiol levels with low-dose vaginal estrogens
10.1097/gme.0000000000001463 · 2020 · External reference
A factor analytic study of climacteric symptoms
10.1016/0022-3999(76)90005-2 · 1976 · External reference
Constructing a standard climacteric scale
10.1016/s0378-5122(98)00025-5 · 1998 · External reference
Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: a systematic review and meta-analysis
10.1007/s10549-016-4002-x · 2016 · External reference
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society
10.1097/gme.0000000000001609 · 2020 · External reference
Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus
10.1097/aog.0000000000004601 · 2021 · External reference
The British menopause society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women with treated for early breast cancer
10.1177/20533691221122358 · 2022 · External reference
Team AS. Testosterone for low libido in postmenopausal women not taking estrogen
10.1056/nejmoa0707302 · 2008 · External reference
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes
10.1016/j.esmoop.2024.102236 · 2024 · External reference
Addressing sexual health in breast cancer survivors: evidence-based practices and clinical considerations
10.1007/s11864-025-01309-5 · 2025 · External reference
Non-hormonal treatments for menopausal symptoms
10.1136/bmj.j5101 · 2017 · External reference
Evidence based medicine: what it is and what it isn’t
10.1136/bmj.312.7023.71 · 1996 · External reference
Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors
10.1200/jco.2014.32.26_suppl.109 · 2014 · External reference
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102
2021 · External reference
Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy
10.1186/s13058-024-01886-7 · 2024 · External reference
